Phase 3 trials

Clinical studies have demonstrated the efficacy and safety of Rapiscan in patients indicated for pharmacologic stress radionuclide MPI.

The efficacy and safety of Rapiscan were determined relative to adenosine in two randomised, double-blind studies titled Adenosine Versus ADenoscan® (adenosine injection) Versus RegAdenosoN Comparative Evaluation for Myocardial Perfusion Imaging (ADVANCE MPI 1 and ADVANCE MPI 2) in 2,015 patients with known or suspected coronary artery disease who were referred for a clinically-indicated pharmacologic stress MPI.1-3


  1. Iskandrian AE, Bateman TM, Belardinelli L, et al. Adenosine versus Rapiscan comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007;14:645-658 (View abstract)
  2. Cerqueira MD et al, on behalf of the ADVANCE MPI Trial Investigators. Effects of age, gender, obesity and diabetes on the efficacy and safety of the selective A2A agonist Rapiscan versus adenosine: integrated ADVANCE MPI trial results.  J Am Coll Cardiol 2008;1:307-316
  3. Mahmarian JJ, Cerqueira MD, Iskandrian AE, et al. Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial. JACC Cardiovasc Imaging 2009;2(8):959-68 (View abstract)